Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology.

Autor: Schauer SP; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA., Toth B; Department of Data and Statistical Sciences, Immunology, Infectious Diseases, and Ophthalmology, Genentech Inc., South San Francisco, California, USA., Lee J; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA., Honigberg LA; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA., Ramakrishnan V; Department of Clinical Pharmacology, Modeling and Simulation, Development Sciences, Genentech Inc., South San Francisco, California, USA., Jiang J; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA., Kollmorgen G; Roche Diagnostics, GmbH, Penzberg, Germany., Bayfield A; Roche Diagnostics, GmbH, Penzberg, Germany., Wild N; Roche Diagnostics, GmbH, Penzberg, Germany., Hoffman J; Department of Translational Medicine, Operations Diagnostics Technology Innovation, Genentech Inc., South San Francisco, California, USA., Ceniceros R; Department of Early Clinical Development, Clinical Operations, Genentech Inc., South San Francisco, California, USA., Dolton M; Department of Clinical Pharmacology, Modeling and Simulation, Development Sciences, Genentech Inc., South San Francisco, California, USA., Bohórquez SMS; Department of Early Clinical Development, Clinical Imaging Group, Genentech Inc., South San Francisco, California, USA., Hoogenraad CC; Department of Neuroscience, Genentech Inc., South San Francisco, California, USA., Wildsmith KR; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA., Teng E; Department of Early Clinical Development, OMNI, Genentech Inc., South San Francisco, California, USA., Monteiro C; Department of Early Clinical Development, OMNI, Genentech Inc., South San Francisco, California, USA., Anania V; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA., Yeh FL; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA.

Publikováno v: Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2024 Nov 08. Date of Electronic Publication: 2024 Nov 08.

Primate cerebrospinal fluid CHI3L1 reflects brain TREM2 agonism.

Autor: Schauer SP; Department of Translational Medicine, Genentech, Inc., South San Francisco, California, USA., Cho CH; Department of Human Pathobiology and OMNI Reverse Translation, Genentech, Inc., South San Francisco, California, USA., Novikova G; Department of Bioinformatics, Genentech, Inc., South San Francisco, California, USA., Roth GA; Department of Preclinical and Translational Pharmacokinetics and Pharmacodynamics, Genentech, Inc., South San Francisco, California, USA., Lee J; Department of Translational Medicine, Genentech, Inc., South San Francisco, California, USA., Sharma AD; Department of Human Pathobiology and OMNI Reverse Translation, Genentech, Inc., South San Francisco, California, USA., Foley AR; Department of BioAnalytical Sciences, Genentech, Inc., South San Francisco, California, USA., Ng C; Department of BioAnalytical Sciences, Genentech, Inc., South San Francisco, California, USA., Shen P; Department of Safety Assessment Pathology, Genentech, Inc., South San Francisco, California, USA., Choi M; Department of Microchemistry, Proteomics, Lipidomics, and Next Generation Sequencing, Genentech, Inc., South San Francisco, California, USA., Ma TP; Department of Microchemistry, Proteomics, Lipidomics, and Next Generation Sequencing, Genentech, Inc., South San Francisco, California, USA., Phu L; Department of Microchemistry, Proteomics, Lipidomics, and Next Generation Sequencing, Genentech, Inc., South San Francisco, California, USA., Budayeva HG; Department of Microchemistry, Proteomics, Lipidomics, and Next Generation Sequencing, Genentech, Inc., South San Francisco, California, USA., Cheung TK; Department of Microchemistry, Proteomics, Lipidomics, and Next Generation Sequencing, Genentech, Inc., South San Francisco, California, USA., Lalehzadeh G; Department of Neuroscience, Genentech, Inc., South San Francisco, California, USA., Imperio J; Department of Neuroscience, Genentech, Inc., South San Francisco, California, USA., Ngu H; Department of Research Pathology, Genentech, Inc., South San Francisco, California, USA., Etxeberria A; Department of Neuroscience, Genentech, Inc., South San Francisco, California, USA., Liang Y; Department of Microchemistry, Proteomics, Lipidomics, and Next Generation Sequencing, Genentech, Inc., South San Francisco, California, USA., Rezzonico MG; Department of Bioinformatics, Genentech, Inc., South San Francisco, California, USA., Dourado M; Department of Neuroscience, Genentech, Inc., South San Francisco, California, USA., Huang K; Department of Translational Medicine, Genentech, Inc., South San Francisco, California, USA., Lai Z; Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California, USA., Hokom M; Department of BioAnalytical Sciences, Genentech, Inc., South San Francisco, California, USA., Pandya NJ; Department of Human Pathobiology and OMNI Reverse Translation, Genentech, Inc., South San Francisco, California, USA., Newton D; Roche Informatics, Hoffmann-La Roche, Ltd., Mississauga, Ontario, Canada., Abdel-Haleem AM; Roche Informatics, Hoffmann-La Roche, Ltd., Mississauga, Ontario, Canada., Chan P; Department of Biochemical and Cellular Pharmacology, Genentech, Inc., South San Francisco, California, USA., Lee D; Department of Safety Assessment Toxicology, Genentech, Inc., South San Francisco, California, USA., Tassew NG; Department of Safety Assessment Toxicology, Genentech, Inc., South San Francisco, California, USA., Sangaraju D; Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California, USA., O'Connor D; Department of Chemistry, Manufacturing, and Controls, Genentech, Inc., South San Francisco, California, USA., Hötzel I; Department of Antibody Engineering, Genentech, Inc., South San Francisco, California, USA., Stark KL; Department of Neuroscience, Genentech, Inc., South San Francisco, California, USA., Chou C; Department of Safety Assessment Nonclinical Operations, Genentech, Inc., South San Francisco, California, USA., Foreman O; Department of Research Pathology, Genentech, Inc., South San Francisco, California, USA., Easton A; Department of Neuroscience, Genentech, Inc., South San Francisco, California, USA., Wildsmith KR; Department of Translational Medicine, Genentech, Inc., South San Francisco, California, USA., Sperinde G; Department of BioAnalytical Sciences, Genentech, Inc., South San Francisco, California, USA., Rose CM; Department of Microchemistry, Proteomics, Lipidomics, and Next Generation Sequencing, Genentech, Inc., South San Francisco, California, USA., Friedman BA; Department of Bioinformatics, Genentech, Inc., South San Francisco, California, USA., Fuji RN; Department of Safety Assessment Pathology, Genentech, Inc., South San Francisco, California, USA., Weimer RM; Department of Translational Imaging, Genentech, Inc., South San Francisco, California, USA., Meilandt WJ; Department of Neuroscience, Genentech, Inc., South San Francisco, California, USA., Sadekar S; Department of Preclinical and Translational Pharmacokinetics and Pharmacodynamics, Genentech, Inc., South San Francisco, California, USA., Nugent AA; Department of Human Pathobiology and OMNI Reverse Translation, Genentech, Inc., South San Francisco, California, USA., Biever A; Department of Translational Medicine, Genentech, Inc., South San Francisco, California, USA.

Publikováno v: Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2024 Sep; Vol. 20 (9), pp. 5861-5888. Date of Electronic Publication: 2024 Aug 01.

Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease.

Autor: Ayalon G; Department of Neuroscience, Genentech Inc., San Francisco, CA 94080, USA., Lee SH; Department of Neuroscience, Genentech Inc., San Francisco, CA 94080, USA., Adolfsson O; AC Immune SA, EPFL Innovation Park, Building B, CH-1015 Lausanne, Switzerland., Foo-Atkins C; Project Team Leadership, Genentech Inc., San Francisco, CA 94080, USA., Atwal JK; Department of Neuroscience, Genentech Inc., San Francisco, CA 94080, USA., Blendstrup M; Department of Early Clinical Development, Genentech Inc., San Francisco, CA 94080, USA., Booler H; Department of Safety Assessment, Genentech Inc., San Francisco, CA 94080, USA., Bravo J; Department of Safety Assessment, Genentech Inc., San Francisco, CA 94080, USA., Brendza R; Department of Neuroscience, Genentech Inc., San Francisco, CA 94080, USA., Brunstein F; Department of Licensing and Early Development Safety, Genentech Inc., San Francisco, CA 94080, USA., Chan R; Department of Protein Chemistry, Genentech Inc., San Francisco, CA 94080, USA., Chandra P; Department of Clinical Pharmacology, Genentech Inc., San Francisco, CA 94080, USA., Couch JA; Project Team Leadership, Genentech Inc., San Francisco, CA 94080, USA., Datwani A; Department of Bioanalytical Sciences, Genentech Inc., San Francisco, CA 94080, USA., Demeule B; Department of Late Stage Pharmaceutical Development, Genentech Inc., San Francisco, CA 94080, USA., DiCara D; Department of Antibody Engineering, Genentech Inc., San Francisco, CA 94080, USA., Erickson R; Department of Bioanalytical Sciences, Genentech Inc., San Francisco, CA 94080, USA., Ernst JA; Department of Protein Chemistry, Genentech Inc., San Francisco, CA 94080, USA., Foreman O; Department of Pathology, Genentech Inc., San Francisco, CA 94080, USA., He D; Department of Biochemical and Cellular Pharmacology, Genentech Inc., San Francisco, CA 94080, USA., Hötzel I; Department of Antibody Engineering, Genentech Inc., San Francisco, CA 94080, USA., Keeley M; Project Team Leadership, Genentech Inc., San Francisco, CA 94080, USA., Kwok MCM; Department of Protein Chemistry, Genentech Inc., San Francisco, CA 94080, USA., Lafrance-Vanasse J; Department of Protein Chemistry, Genentech Inc., San Francisco, CA 94080, USA., Lin H; Department of Neuroscience, Genentech Inc., San Francisco, CA 94080, USA., Lu Y; Department of Biochemical and Cellular Pharmacology, Genentech Inc., San Francisco, CA 94080, USA., Luk W; Department of Biochemical and Cellular Pharmacology, Genentech Inc., San Francisco, CA 94080, USA., Manser P; Biostatistics, Genentech Inc., San Francisco, CA 94080, USA., Muhs A; AC Immune SA, EPFL Innovation Park, Building B, CH-1015 Lausanne, Switzerland., Ngu H; Department of Pathology, Genentech Inc., San Francisco, CA 94080, USA., Pfeifer A; AC Immune SA, EPFL Innovation Park, Building B, CH-1015 Lausanne, Switzerland., Pihlgren M; AC Immune SA, EPFL Innovation Park, Building B, CH-1015 Lausanne, Switzerland., Rao GK; Department of Safety Assessment, Genentech Inc., San Francisco, CA 94080, USA., Scearce-Levie K; Department of Neuroscience, Genentech Inc., San Francisco, CA 94080, USA., Schauer SP; Department of Biomarker Development, Genentech Inc., San Francisco, CA 94080, USA., Smith WB; Alliance for Multispecialty Research, University of Tennessee Medical Center, Knoxville, TN 37920, USA., Solanoy H; Department of Neuroscience, Genentech Inc., San Francisco, CA 94080, USA., Teng E; Department of Early Clinical Development, Genentech Inc., San Francisco, CA 94080, USA., Wildsmith KR; Department of Biomarker Development, Genentech Inc., San Francisco, CA 94080, USA., Bumbaca Yadav D; Department of Preclinical and Translational Pharmacokinetics and Pharmacodynamics, Genentech Inc., San Francisco, CA 94080, USA., Ying Y; Department of Bioanalytical Sciences, Genentech Inc., San Francisco, CA 94080, USA., Fuji RN; Department of Safety Assessment, Genentech Inc., San Francisco, CA 94080, USA. fuji.reina@gene.com., Kerchner GA; Department of Early Clinical Development, Genentech Inc., San Francisco, CA 94080, USA.

Publikováno v: Science translational medicine [Sci Transl Med] 2021 May 12; Vol. 13 (593).

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).

Autor: Salloway S; Department of Neurology and Psychiatry, The Warren Alpert Medical School of Brown University, 345 Blackstone Boulevard, Providence, RI, 2906, USA. ssalloway@butler.org., Honigberg LA; Genentech Inc., South San Francisco, CA, USA., Cho W; Genentech Inc., South San Francisco, CA, USA., Ward M; Genentech Inc., South San Francisco, CA, USA., Friesenhahn M; Genentech Inc., South San Francisco, CA, USA., Brunstein F; Genentech Inc., South San Francisco, CA, USA., Quartino A; Genentech Inc., South San Francisco, CA, USA., Clayton D; Genentech Inc., South San Francisco, CA, USA., Mortensen D; Genentech Inc., South San Francisco, CA, USA., Bittner T; F Hoffmann-La Roche Ltd., Basel, Switzerland., Ho C; Genentech Inc., South San Francisco, CA, USA., Rabe C; Genentech Inc., South San Francisco, CA, USA., Schauer SP; Genentech Inc., South San Francisco, CA, USA., Wildsmith KR; Genentech Inc., South San Francisco, CA, USA., Fuji RN; Genentech Inc., South San Francisco, CA, USA., Suliman S; Genentech Inc., South San Francisco, CA, USA., Reiman EM; Banner Alzheimer's Institute, Phoenix, AZ, USA., Chen K; Banner Alzheimer's Institute, Phoenix, AZ, USA., Paul R; Genentech Inc., South San Francisco, CA, USA.

Publikováno v: Alzheimer's research & therapy [Alzheimers Res Ther] 2018 Sep 19; Vol. 10 (1), pp. 96. Date of Electronic Publication: 2018 Sep 19.

Mechanistic pharmacokinetic-pharmacodynamic modeling of BACE1 inhibition in monkeys: development of a predictive model for amyloid precursor protein processing.

Autor: Liu X; Genentech Inc., MS 41-2A, 1 DNA Way, South San Francisco, CA 94080, USA. liu.xingrong@gene.com, Wong H, Scearce-Levie K, Watts RJ, Coraggio M, Shin YG, Peng K, Wildsmith KR, Atwal JK, Mango J, Schauer SP, Regal K, Hunt KW, Thomas AA, Siu M, Lyssikatos J, Deshmukh G, Hop CE

Publikováno v: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2013 Jul; Vol. 41 (7), pp. 1319-28. Date of Electronic Publication: 2013 Apr 12.